Zhong JH. Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era. World J Gastroenterol 2024; 30(8): 806-810 [PMID: 38516235 DOI: 10.3748/wjg.v30.i8.806]
Corresponding Author of This Article
Jian-Hong Zhong, Doctor, PhD, Academic Editor, Doctor, Professor, Surgeon, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. zhongjianhong@gxmu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 28, 2024; 30(8): 806-810 Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.806
Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era
Jian-Hong Zhong
Jian-Hong Zhong, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Author contributions: Zhong JH wrote and revised the manuscript.
Supported bythe Specific Research Project of Guangxi for Research Bases and Talents, No. GuiKe AD22035057; and the National Natural Science Foundation of China, No. 82060510 and No. 82260569.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Hong Zhong, Doctor, PhD, Academic Editor, Doctor, Professor, Surgeon, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. zhongjianhong@gxmu.edu.cn
Received: December 10, 2023 Peer-review started: December 10, 2023 First decision: December 27, 2023 Revised: December 27, 2023 Accepted: January 31, 2024 Article in press: January 31, 2024 Published online: February 28, 2024
Abstract
Approximately 50%-70% of patients with hepatocellular carcinoma experience recurrence within five years after curative hepatic resection or ablation. As a result, many patients receive adjuvant therapy after curative resection or ablation in order to prolong recurrence-free survival. The therapy recommended by national guidelines can differ, and guidelines do not specify when to initiate adjuvant therapy or how long to continue it. These and other unanswered questions around adjuvant therapies make it difficult to optimize them and determine which may be more appropriate for a given type of patient. These questions need to be addressed by clinicians and researchers.
Core Tip: Several questions need to be addressed by clinical researchers about the use of adjuvant therapy to prolong recurrence-free survival of patients with hepatocellular carcinoma following potentially curative treatment.
